VYGRNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Voyager Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 6, 2026
$2.05+0.15 (+7.89%)
Close on Oct 19, 2026
- Market cap
- $124.12M
- P/E (TTM)
- –
- Dividend yield
- –
Share price
−$2.90 (−58.59%)past year
Daily closes, adjusted for splits. Drag across the chart to measure a change.Earnings
Voyager Therapeutics, Inc. saw revenue fall 19.1% to $34.46M over the twelve months to Jun 30, 2026. Free cash flow was -$121.42M.
Revenue
$34.46M
-19.1% vs. a year earlier
Operating income
-$117.19M
TTM Q2 2026
Free cash flow
-$121.42M
TTM Q2 2026
EPS, diluted
-$1.81
TTM Q2 2026
Key statistics
Valuation at the latest close; fundamentals over the trailing twelve months, balances at Jun 30, 2026
Valuation
- Market cap
- $124.12M
- P/E ratio
- –
- Price to sales
- 3.60
- Price to book
- 0.80
- Dividend yield
- –
- Free cash flow yield
- -97.82%
Fundamentals
- Revenue
- $34.46M
- Net income
- -$107.73M
- EPS, diluted
- -$1.81
- Free cash flow
- -$121.42M
- Book value per share
- $2.55
- Diluted shares
- 61M
Thirteen years at a glance
Fiscal years 2013 to 2025 and trailing twelve months, USD
Revenue
$34.46M-19.1% YoY
Operating income
-$117.19M
Net income
-$107.73M
EPS, diluted
-$1.81
Free cash flow
-$121.42M
Reported periodTrailing twelve months